Hematology-Oncology – Page 3

Targeting Leukemia Stem Cells in Unfit Acute Myeloid Leukemia with a CD70-Directed Third Agent: Promise and Caveats from the ELEVATE Trial

By MedXY 10/08/2026

This review synthesizes evidence from the ELEVATE trial on adding cusatuzumab, a CD70-targeting antibody, to venetoclax with or without azacitidine in unfit AML patients, highlighting therapeutic potential, safety concerns, and translational insights.

Clinical Updates Hematology-Oncology news

CD25-based Graft-versus-Host Disease Prophylaxis after Haploidentical Hematopoietic Stem Cell Transplantation: Comparative Analysis of Two Prophylactic Regimens

By MedXY 10/08/2026

This review synthesizes emerging evidence comparing high-dose anti-CD25 (without methotrexate) versus low-dose anti-CD25 (with methotrexate) strategies for GVHD prophylaxis in haplo-HSCT, highlighting improved acute GVHD control and GRFS with the former approach.

Hematology-Oncology news

Influence of Clonal Hematopoiesis and Neutropenia on CAR-T Therapy Outcomes in Hematologic Malignancies

By MedXY 10/08/2026

CHIP and pre-treatment neutropenia do not significantly affect survival or main toxicities in CAR-T therapy for hematologic cancers but may predict specific inflammatory toxicities, indicating distinct risk profiles for patient management.

Hematology-Oncology news Oncology

Targeting Leukemic Stem Cells in AML: Overcoming PI3K Inhibitor Resistance through Epigenetic Modulation

By MedXY 10/08/2026

This article explores novel therapeutic strategies in acute myeloid leukemia by combining PI3K inhibitors with EZH1/2 dual inhibitors to overcome epigenetic resistance mechanisms in leukemic stem cells, offering promising pathways to prevent relapse.

Hematology-Oncology news

Targeting ROR1 in Chronic Lymphocytic Leukemia: Insights from the Zilovertamab and Ibrutinib Combination in High-Risk del(17p) Disease

By MedXY 10/08/2026

A phase 1b/2 study evaluating zilovertamab combined with ibrutinib in relapsed/refractory CLL reveals safety, mechanistic inhibition of ROR1 signaling pathways, and a potential efficacy signal in del(17p) patients warranting further studies.

Hematology-Oncology news Oncology

Long-Term Efficacy and Safety of First-Line Ibrutinib-Venetoclax in Older Patients with Chronic Lymphocytic Leukemia: Insights from the 67-Month GLOW Study

By MedXY 10/08/2026

The GLOW phase III trial demonstrates that fixed-duration ibrutinib-venetoclax provides superior overall survival, progression-free survival, and safety compared to chlorambucil-obinutuzumab in older/comorbid CLL patients, with durable disease control and reduced need for second-line therapy.

Dermatology Hematology-Oncology news

Decoding CTCL: A Single-Cell Atlas Reveals Oncogenic Pathways and Immune Resistance Mechanisms

By MedXY 10/08/2026

This study presents a comprehensive single-cell RNA-sequencing atlas of CTCL, identifying oncogenic transcriptional programs and immune microenvironment features that offer new therapeutic targets for advanced-stage disease.

Cardiology Hematology-Oncology news

Unraveling the Mechanistic Role of Syndecan-4 and Piezo1 in Deep Vein Thrombosis: Therapeutic Insights from Quercetin

By MedXY 10/07/2026

This study reveals that syndecan-4 shedding exacerbates deep vein thrombosis by promoting Piezo1-dependent endothelial-mesenchymal transition, with quercetin showing promise as a novel therapeutic Piezo1 inhibitor.

Hematology-Oncology Neurology news

Midterm Cognitive Outcomes After CAR T-Cell Therapy in CNS Lymphoma Patients: Encouraging Evidence Beyond Acute Neurotoxicity

By MedXY 10/05/2026

This study assesses medium-term cognitive changes in CNS lymphoma patients treated with CAR T-cell therapy, revealing cognitive stability or improvement up to 12 months post-treatment, despite initial neurotoxicity risks.

$CAR T-Cell Therapy Revolutionizes Outcomes in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: Insights from Pooled REPRIME-FIL and CART-SIE Analyses$

Hematology-Oncology news Oncology

CAR T-Cell Therapy Revolutionizes Outcomes in Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma: Insights from Pooled REPRIME-FIL and CART-SIE Analyses

By MedXY 10/01/2026

A pooled analysis of REPRIME-FIL and CART-SIE studies shows CAR T-cell therapy significantly improves overall survival in relapsed/refractory primary mediastinal B-cell lymphoma compared to traditional salvage treatments including ASCT.

Hematology-Oncology news Oncology

Efficacy and Safety of BCMA-Targeted CAR T Therapy as Salvage Treatment in Multiple Myeloma Post-GPRC5D CAR T-Cell Failure

By MedXY 10/01/2026

BCMA-targeted CAR T-cell therapy demonstrates substantial efficacy and an acceptable safety profile as a salvage option for relapsed/refractory multiple myeloma patients after failure of prior anti-GPRC5D CAR T-cell treatments.

$Synergistic Therapy with Venetoclax and Inotuzumab Ozogamicin Shows Promising Outcomes in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia$

Hematology-Oncology news

Synergistic Therapy with Venetoclax and Inotuzumab Ozogamicin Shows Promising Outcomes in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

By MedXY 10/01/2026

A phase 1 trial demonstrates that venetoclax combined with inotuzumab ozogamicin is safe and highly effective in producing durable MRD-negative remissions in relapsed/refractory B-cell ALL and lymphoblastic lymphoma.

Hematology-Oncology news Oncology

You Are Already Trained for This: Harnessing Hematology-Oncology Expertise in Radiation Mass Casualty Management

By MedXY 10/01/2026

Hematologists and oncologists possess critical skills to address hematologic complications of acute radiation syndrome and are essential in bolstering mass casualty radiation response, utilizing existing resources and infrastructure for efficient patient care.

Hematology-Oncology news

Venetoclax Combined with Pediatric-Inspired Chemotherapy Enhances Outcomes in Adolescents and Adults with Ph-Negative Acute Lymphoblastic Leukemia

By MedXY 10/01/2026

A phase 2 trial demonstrates that adding venetoclax to pediatric chemotherapy regimens in adolescents and adults with newly diagnosed Philadelphia chromosome-negative ALL significantly improves MRD negativity and survival with manageable toxicity.

Hematology-Oncology news

Harnessing Expanded Antigen-Specific Donor Regulatory T Cells to Prevent GVHD in Allogeneic Hematopoietic Cell Transplantation

By MedXY 10/01/2026

A phase 1 trial demonstrates the safety and promising efficacy of expanded minor histocompatibility antigen-specific donor regulatory T cells as a novel prophylactic approach to reduce graft-versus-host disease and improve survival post-allogeneic hematopoietic cell transplantation.

Hematology-Oncology news

Evolving First-Line Treatments in Primary Mediastinal B-Cell Lymphoma: Insights from a Nationwide Italian Retrospective Study

By MedXY 09/30/2026

This retrospective nationwide study from Italy evaluates real-life first-line treatments for primary mediastinal B-cell lymphoma, highlighting treatment patterns, clinical outcomes, and challenges in managing this rare lymphoma subtype.

Hematology-Oncology news Oncology

Transforming Care in Follicular Lymphoma: Outcomes and Prognostic Insights in the Rituximab Era

By MedXY 09/30/2026

This study analyzes treatment patterns, outcomes, and prognostic factors in 344 patients with transformed follicular lymphoma in the rituximab era, revealing poor event-free survival but moderate overall survival and high relapse rates, guiding future clinical strategies.

Hematology-Oncology news

Harnessing Antigen-Specific Donor Regulatory T Cells to Prevent GVHD in Allogeneic Hematopoietic Cell Transplantation

By MedXY 09/30/2026

This phase 1 trial demonstrates that expanded minor histocompatibility antigen-specific donor regulatory T cells, combined with sirolimus prophylaxis, are safe and show promise in preventing acute and chronic GVHD post-allogeneic HCT with durable in vivo persistence.

Hematology-Oncology news

Targeting Galectin-1 to Mitigate Monocyte-Driven Hyperinflammation in Myeloproliferative Neoplasms

By MedXY 09/30/2026

This article explores the pivotal role of Galectin-1 in enhancing monocyte-mediated inflammation in myeloproliferative neoplasms (MPNs) and highlights its potential as a novel therapeutic target through the TLR4-NF-κB signaling axis.

Hematology-Oncology news Oncology

Targeting NSD2 Degradation: A Novel Therapeutic Avenue for High-Risk t(4;14) Multiple Myeloma

By MedXY 09/30/2026

This article explores the discovery of NSD2-ligand-directed degrader (NSD2-LDD), a promising targeted therapy that degrades oncogenic NSD2 in t(4;14) multiple myeloma, reversing malignant epigenomic programs and improving disease outcomes in preclinical models.